2024 Review: Leading the Future with TFT Semiconductor Technology

2025-01-02

On the occasion of the New Year’s beginning, we reflect on the year 2024, which was marked by business growth, global expansion, and meaningful partnerships. We’re delighted to share these highlights with you!

– First of all, we are very excited to announce that we have completed A Round Financing, funded by Proxima Ventures.

– Our bio-semiconductor BU has rapidly launched our first standard product, offering world-leading technical specifications. Currently, the TruArray™ Std 4K high-throughput oligonucleotide microarray has started taking orders. And the 4K oligo pool, as well as the 65K/131K oligonucleotide microarray, will be launched soon in 2025. Please stay tuned with us!

– The optoelectronic BU has achieved growth despite a challenging market environment, with the sales revenue of the TruEbox series soaring by 80%, the sensing system product line growing by over 150%, and the display system product line increasing by nearly 100%. Additionally, we have launched three new products, continuously expanding our optoelectronic product lines.

– Last but not least, the number of LinkZill customers has surpassed 300, covering more than 20 countries and regions globally, with overseas business accounting for 21% of our total revenue.

We are grateful to everyone who has been part of our journey, and we look forward to continuing our path forward, leveraging these successes to embark on the next chapter of innovation and reach even greater milestones in 2025!

Click here to learn more👉Annual summary of LinkZill

 

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.

康康   博士

合伙人兼首席生物信息官

博士毕业于香港大学生物信息和系统生物学专业,后任德国莱布尼茨协会科学合作者、丹麦科技大学诺和诺德生物可持续研究中心访问科学家。曾先后担任华大基因科学家,参与创立了华大基因合成生物学研究方向;微基因资深生物信息工程师、品牌顾问;倍生生物联合创始人兼首席信息科学家。他专注于合成生物学、组学和高通量技术10余年,同时也是生物技术领域颇具影响力的「行业KOL」。2023年3月加入领挚科技,负责半导体生命科学工具方向与产品规划。